Skip to main content
. 2021 Aug 25:10.2217/imt-2021-0007. doi: 10.2217/imt-2021-0007

Figure 4. The impact of prior PD-1 exposure on the prognosis of COVID-19 in patients with lung cancer.

Figure 4.

Patients were redistributed into five groups: no prior PD-1, interval >6 months (>6 mo), interval between 6 months and 6 weeks (6 mo–6 w), interval <6 weeks (<6 w) and initial dose within 3 months (start <3 mo). (A) Rate of hospitalization compared between no prior PD-1 and >6 mo (p = 0.48), 6 mo–6 w (p = 026), <6 w (p = 0.17) and start <3 mo (p = 0.30). (B) Rate of severe disease compared between no prior PD-1 and >6 mo (p = 1.00), 6 mo–6 w (p = 0.26), <6 w (p = 0.38) and start <3 mo (p = 0.48). (C) Rate of death compared between no prior PD-1 and >6 mo (p = 0.24), 6 mo–6 w (p = 0.24), <6 w (p = 1.00) and start <3 mo (p = 0.68).

mo: Month; w: Week.

Data taken from [23].